TinyGemsBreaks Archive - Page 118 of 121

ThursdayJun 09, 2022 2:41 pm

TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Engages IBN for Corporate Communications Expertise

Aditxt (NASDAQ: ADTX), a biotech innovation company, today announced that it has selected the corporate communications expertise of IBN (“InvestorBrandNetwork”), a multifaceted financial news and publishing company for private and public entities. As part of the relationship, IBN will leverage its investor based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs, and other outreach tools to generate greater awareness for Aditxt. “The potential market opportunities presented by immune monitoring and reprogramming are extensive. Through its work in the COVID-19 testing market with AditxtScore(TM), Aditxt demonstrated this potential. The company is now…

ThursdayJun 09, 2022 2:21 pm

TinyGemsBreaks – SRAX Inc. (NASDAQ: SRAX), Rogue Station Companies Inc./Everdime Inc. (RGST) Enter Partnership to Enhance Investor Communications

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, has entered a partnership with Rogue Station Companies/Everdime (OTC: RGST). Through SRAX, RGST, a crypto and blockchain development company building the technology bridge that connects what is real and the new augmented reality within the metaverse, will have the ability to further reach its community through sophisticated solutions. “The RGST/Everdime team warmly welcomes our recent partnership with SRAX,” said RGST CEO Sandor Miklos. “As our company continues BETA testing its apps and prepares to launch its token and…

ThursdayJun 09, 2022 2:11 pm

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Portfolio of Rare Cannabinoids with Launch of d9-THCV

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced its launch of B2B sales of the rare cannabinoid delta 9-dominant tetrahydrocannabivarin (“d9-THCV”) into the health and wellness sector via its wholly owned subsidiary, BayMedica LLC. “We are very excited to launch our highly anticipated d9-THCV and further enhance BayMedica’s growing product portfolio,” said Shane Johnson, MD, SVP and general manager of BayMedica. “THCV is one of the few rare cannabinoids that has been researched in early clinical trials for various therapeutic effects, fueling significant interest by end-product manufacturers and consumers alike.…

WednesdayJun 08, 2022 12:16 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Grants DehydraTECH(TM) License to Ireland-Based AnodGen Bioceuticals

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the awarding of a five-year, non-exclusive DehydraTECH(TM) license from its wholly-owned subsidiary, Lexaria Pharmaceutical Corp., to AnodGen Bioceuticals of Ireland. According to the update, the awarded license is valid for the manufacturing and distribution of DehydraTECH-processed cannabinoid active pharmaceutical ingredient (“API”) powders within Europe including the U.K., Australia and New Zealand; including pharmaceutical and medical product applications for psychoactive cannabinoids and medical product applications for non-psychoactive cannabinoids. AnodGen, which has the right to manufacture and sell these API powders to third party companies for their own…

WednesdayJun 08, 2022 11:59 am

TinyGemsBreaks – SRAX Inc.’s (NASDAQ: SRAX) Upcoming Event to Highlight Prominent Names and Companies in Decentralized Web Space

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, today announced that the Sequire Decentralized Web Conference will take place on June 23, 2022. As blockchain, DAOs, NFTS and digital currencies take off around the world with far-reaching potential, SRAX is bringing together a list of influential companies making history in this sector for a full day of presentations. Nearly nine million active small-cap investors were invited to the event, which will feature over 15 decentralized web focused companies and keynotes highlighting prominent names in this space.…

TuesdayJun 07, 2022 11:02 am

TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Acquisition of Entheon Biomedical’s DMT Clinical Study

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has entered an agreement to acquire the largest phase 1 DMT study conducted to date. The acquisition, conducted through Cybin IRL Limited, a wholly owned subsidiary of Cybin, is expected to accelerate Cybin’s CYB004 program timeline by an estimated nine months; CYB004 is Cybin’s proprietary deuterated DMT molecule designed for the potential treatment of anxiety disorders.. The phase 1 N,N-dimethyltryptamine (“DMT”) study is focused on evaluating pharmacokinetics/pharmacodynamics of DMT currently underway and is expected to significantly impact the clinical path forward. Renamed CYB004-E, the phase 1 EBRX-101…

TuesdayJun 07, 2022 10:08 am

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Closes $5M Direct, Private Placement Offerings

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has closed on its registered direct offering and concurrent private placement with a single healthcare-focused institutional investor; the offerings were priced at-the-market under Nasdaq rules. According to the announcement, for the registered direct offering, INM issued 4,079,256 common shares at a purchase price of $0.858 per share (or prefunded warrant in lieu thereof). For the concurrent private placement, InMed issued and sold to the investor 1,748,250 common shares (or prefunded warrant in lieu thereto); those shares were offered at the same purchase price as…

MondayJun 06, 2022 3:32 pm

TinyGemsBreaks – Knightscope Inc. (NASDAQ: KSCP) Earns “In-Process” Rating from US Government FedRAMP Program

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies committed to enhancing U.S. security operations, announced that as part of its efforts to pursue Authority to Authorize (“ATO”) in the Federal Risk and Authorization Management Program (“FedRAMP”), the company achieved “In-Process” status. A government-wide program that promotes the adoption of secure cloud services across the federal government, FedRAMP provides a standardized approach to security assessment and authorization, and provides continuous monitoring for cloud products and services. Knightscope has been working to design a secure, hardened environment specifically to support government clients; as part of those efforts, the company built…

MondayJun 06, 2022 3:11 pm

TinyGemsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) Immune Monitoring Platform ‘Is the Right Technology at the Right Time’

Aditxt (NASDAQ: ADTX) recently entered into a multi-year partnership with Guthy-Renker LLC- affiliated GRS. The partnership focuses on building awareness and visibility among consumers and health care providers for the proprietary AditxtScore(TM) Immune Monitoring Platform. “AditxtScore is the right technology at the right time. Our first application, AditxtScore for COVID-19, delivers timely reports on vulnerability and immune status to SARS-CoV-2 and its known variants, giving consumers and their physicians the data they need to make informed health decisions for themselves and their families,” Aditxt CEO and Co-Founder Amro Albanna was quoted in a recent article. Albanna added that the company’s…

MondayJun 06, 2022 2:04 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Takes First Regulatory Step with FDA for Development of DehydraTECH-CBD in Treating Hypertension

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has successfully filed a pre-Investigational New Drug (“IND”) meeting request letter with the U.S. Food and Drug Administration (“FDA”). According to the update, the FDA has already responded to and confirmed Lexaria’s filing and has provided a target date of July 30, 2022, subject to certain conditions being met. “We are excited to take this important first regulatory step with the FDA for the development of our DehydraTECH-CBD for the treatment of hypertension,” said John Docherty, president of Lexaria. “Submission of this request letter…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks